Results from INAVO120 in PIK3CA-Mutated HR+/HER2- Locally Advanced/Metastatic Breast Cancer

Opinion
Video

Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
      Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
      Breast Cancer Study Shows Minimal Score Variation After Radiation Boost
      Breast Cancer Study Shows Minimal Score Variation After Radiation Boost
      Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
      Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
      Shortened Radiation Trial Advances Breast Cancer Treatment
      Shortened Radiation Trial Advances Breast Cancer Treatment
      Understanding the Significance of ESR1 Mutations in Breast Cancer
      Understanding the Significance of ESR1 Mutations in Breast Cancer
      42nd Annual Miami Breast Cancer Conference: The Show and After Show
      42nd Annual Miami Breast Cancer Conference: The Show and After Show
      Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 Inhibition
      Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 Inhibition
      Sequencing and AEs Guide Next Steps for Dato-DXd in Breast Cancer
      Sequencing and AEs Guide Next Steps for Dato-DXd in Breast Cancer
      FDA Approves Dato-DXd in HR+, HER2- Breast Cancer Following TROPION-Breast01
      FDA Approves Dato-DXd in HR+, HER2- Breast Cancer Following TROPION-Breast01
      Effective and Well-Tolerated Combo in ER+/HER2– Metastatic Breast Cancer
      Effective and Well-Tolerated Combo in ER+/HER2– Metastatic Breast Cancer
      Related Content
      Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

      Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

      Targeted Oncology Staff
      March 31st 2025
      Article

      During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

      Read More

      Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

      Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

      Jordyn Sava;Aditya Bardia, MD, MPH
      February 6th 2025
      Podcast

      In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

      Listen

      Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBC

      Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBC

      Ashling Wahner
      March 14th 2025
      Article

      In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

      Read More

      Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

      Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

      Jordyn Sava;Sanjay K. Juneja, MD
      January 15th 2025
      Podcast

      In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

      Listen

      Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

      Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

      Tony Berberabe, MPH
      March 8th 2025
      Article

      Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

      Read More

      HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

      HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

      Jordyn Sava
      March 3rd 2025
      Article

      Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as MP-H2.

      Read More